Manager, Manufacturing & Facility Operations

Medical Director

Clinical Trial Manager

Associate Scientist

Accounting Manager

IT Director, Enterprise Applications 

Senior Scientist

Associate, Warehouse Operations and Materials Handling  

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

8Biomed

A-Alpha Bio

A2 Biotherapeutics

AavantiBio

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

ACELYRIN

Acepodia

Achieve Life Sciences

Acrivon Therapeutics

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

adMare BioInnovations

Admera Health

Adverum Biotechnologies

adyn

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agena Bioscience

AIRNA Bio

Akero Therapeutics

Akouos

Alamar Biosciences

Alector

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Theranostics

Alphabioregen

Alpine Immune Sciences

Altis Biosystems

Alto Neuroscience

AltPep

Alumis

Alveo Technologies

Alveolus Bio

ALX Oncology

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AN2 Therapeutics

Anagram Therapeutics

Andes

Angiex

Angiocrine Bioscience

AnHeart Therapeutics

Annexon Biosciences

Anokion

Ansa Biotechnologies

Antheia

Anthos Therapeutics

AOA Dx

Apic Bio

Apollomics

Appia Bio

Applied Molecular Transport

Apriori Bio

Aptevo Therapeutics

Apton Biosystems

Aptose Biosciences

Aquinnah Pharmaceuticals

Aramis Biosciences

Arbor Biotechnologies

Arcadia Science

Arcellx

Arctoris

Arcturus Therapeutics

Arcutis Biotherapeutics

Arima Genomics

Ark Biotech

Arcellx is developing immunotherapies to treat cancer. Chimeric antigen receptor (CAR) T-cells are the latest innovation to identify and eliminate cancer cells, yet there is still more room for improvement. Arcellx’s unique approach involves their novel D-Domain technology, a small, stable, fully synthetic binding agent that can be combined with CARs to improve target specificity and enhance binding affinity. From the D-Domain, Arcellx can generate diverse libraries of proprietary target-binding domains which serve as the foundation of their proprietary ddCAR and ARC-SparX platforms. Arcellx is currently developing cell therapies treatments for multiple myeloma, acute myeloid leukemia and solid tumors, the first of which is now in Phase 2 clinical trials.

<p>Arcellx is developing immunotherapies to treat cancer. Chimeric antigen receptor (CAR) T-cells are the latest innovation to identify and eliminate cancer cells, yet there is still more room for improvement. Arcellx’s unique approach involves their novel D-Domain technology, a small, stable, fully synthetic binding agent that can be combined with CARs to improve target specificity and enhance binding affinity. From the D-Domain, Arcellx can generate diverse libraries of proprietary target-binding domains which serve as the foundation of their proprietary ddCAR and ARC-SparX platforms. Arcellx is currently developing cell therapies treatments for multiple myeloma, acute myeloid leukemia and solid tumors, the first of which is now in Phase 2 clinical trials.</p>


Find a biotech startup job.